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Objective: Given excellent 30-day survival for pediatric cardiac surgery, other
outcome measures are important. We aimed to study important early postopera-
tive morbidities selected by stakeholders following a rigorous and evidenced-
based process, with a view to identifying potential risk factors.
Methods: The incidence of selected morbidities was prospectively measured for
3090 consecutive pediatric cardiac surgical admissions in 5 UK centers between
October 2015 and June 2017. The relationship between the candidate risk factors
and the incidence of morbidities was explored using multiple regressions. Patient
survival, a secondary outcome, was checked at 6 months.
Results: A total of 675 (21.8%) procedure episodes led to at least 1 of the
following: acute neurologic event, unplanned reoperation, feeding problems,
renal replacement therapy, major adverse events, extracorporeal life support,
necrotizing enterocolitis, surgical infection, or prolonged pleural effusion. The
highest adjusted odds ratio of morbidity was in neonates compared with children,
5.26 (95% confidence interval, 3.90-7.06), and complex heart diseases (eg, hypo-
plastic left heart), 2.14 (95% confidence interval, 1.41-3.24) compared with low
complexity (eg, atrial septal defect, P<.001 for all). Patients with any selected
morbidity had a 6-month survival of 88.2% (95% confidence interval, 85.4-
90.6) compared with 99.3% (95% confidence interval, 98.9-99.6) with no defined
morbidity (P<.001).
Conclusions: Evaluation of postoperative morbidity provides important informa-
tion over and above 30-day survival and should become a focus for audit and qual-
ity improvement. Our results have been used to initiate UK-based audit for 5 of
these 9 morbidities, co-develop software for local monitoring of these morbid-
ities, and parent information about these morbidities. (J Thorac Cardiovasc
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The prospective evaluation of selected impor-
tant early morbidities after pediatric cardiac
surgery reveals a hidden burden over and above
what is shown by the current keymetric of early
operative mortality.Perspective
Early survival outcomes of pediatric cardiac
surgery are excellent; thus, there is a strong in-
terest from stakeholders to pursue a wider and
more complex range of outcomes. Our prospec-
tive study in 3090 pediatric cardiac surgeries at
5 of the United Kingdom’s 10 specialist centers
indicated that standardized postoperative
morbidity evaluation provides important data
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What Is Pediatric Cardiac Surgical Morbidity?
Pediatric cardiac surgical morbidity is illness or lack of
health that occurs soon after a cardiac operation, and so
may be regarded as an adverse outcome of surgery.
Although there has been considerable research on
measuring, understanding, and reducing perioperative mor-
tality,1-3 there has been less attention on surgical
morbidities.
Why Does Morbidity After Pediatric Cardiac
Surgery Matter?
Previous research on surgical morbidities after pediatric
cardiac surgery has established their association with longer
stays in hospital and other adverse outcomes, including
death.4,5 For children with some heart conditions,
prolonged postoperative stay in hospital is associated with
higher levels of long-term neurologic disability.6 Prolonged
hospitalization due to morbidities can be expensive to
manage, for example, extracorporeal life support (ECLS)
costs more than £10,000 per day.7 Morbidity, disability,
and quality of life are viewed as key outcomes by patients,
families, and clinical teams who are looking to deliver
further improvements in service quality. In the United
Kingdom, a recent major review of the specialty highlighted
the need to monitor a range of outcomes including
morbidity in a timely and meaningful fashion,8 and com-
missioners of services are appropriately seeking evidence
on outcomes and quality assurance from providers.
Our Study
In previous work, a multidisciplinary group with patient
and caregiver involvement selected a list of 9 key early2 The Journal of Thoracic and Cardiovascular Surgerpostoperativemorbidities9 that they consideredmost impor-
tant, informed by clinical views on definitions and feasi-
bility of routine monitoring.10 The selection process set
out to identify the morbidities likely to have the greatest
impact on patients in terms of hospital stay, mortality, qual-
ity, and cost (to be measured in a subset of patients and pre-
sented separately). Morbidities considered likely to have a
lower impact or to be rare or difficult to reliably define
and measure were not included.
The selected morbidities were ECLS, acute neurologic
event, unplanned reintervention, feeding problems, major
adverse event, prolonged pleural effusion, postsurgical
infection morbidity, renal support, and necrotizing entero-
colitis. A report detailing the definitions for each of these
morbidities has been peer reviewed and published previ-
ously,10 and we include the main table from Brown and col-
leagues10 as Appendix E1. We report the incidence of and
risk factors for these morbidities within the UK pediatric
cardiac surgery population.
MATERIALS AND METHODS
Patient Population
Our study population comprised all children aged less than 17 years un-
dergoing cardiac surgery and open, closed, or hybrid procedures involving
the heart as specified by the National Congenital Heart Disease Audit
(NCHDA)11 at each of 5 participating centers between October 1, 2015,
and June 30, 2017, other than premature babies undergoing persistent duc-
tus arteriosus ligation (who are mainly cared for in neonatal intensive care
units) and children undergoing cardiothoracic transplant or tracheal pro-
cedures. These exclusions were made because these groups experience
different sets of morbidities, and furthermore because of centralization of
services in the United Kingdom, tracheal and transplant procedures are
only carried out in one of the study sites. The participating centers care
for approximately more than half of children with cardiac disease in the
United Kingdom.11
Data Collection
Patients were prospectively monitored for the presence of the 9 early
morbidities selected9 and defined10 in previous work as important and suit-
able for routine monitoring.
Data collection was undertaken prospectively, and morbidities were
attributed to the immediately preceding cardiac surgery and defined within
the same hospitalization other than unplanned reoperation within 30 days
(an unanticipated cardiac procedure within 30 days was a morbidity
outcome; Appendix E1,10 shows details) and mediastinitis (falls within
postoperative infection morbidity, Brown and colleagues,10 and
Appendix E1 shows details), both of which could be identified postdi-
scharge by the operating surgeon and clinical care team.
As for the UK audit of 30-day mortality,12 procedures on the same pa-
tient were included in the analysis of morbidity incidence if they occurred
more than 30 days apart (ie, a new procedure occurring more than 30 days
after the first or index operation was considered a separate clinical episode
of care and included in the analysis as such). Planned operations within
30 days did not contribute to the analysis.
We obtained key clinical data on study patients from the local copy of
NCHDA11 data held at each study site. All data were pseudonymized
before sending them to the study team for analysis. The advantage of har-
nessing NCHDAdata for this study was that each field is clearly and consis-
tently defined. It is mandatory to record every cardiac procedure, and
NCHDA data overall are externally validated.y c- 2019
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NCHDA, removed operations that should have been excluded (eg, elective
chest closures, miscoded interventional catheters), and verified all reoper-
ation morbidities, including double-checking any ambiguous reoperations
with the operating surgeon.
Candidate Risk Factor Variables and Variable
Groups
We prespecified candidate clinical risk factors12,13 in the peer-reviewed
study protocol. Most candidate risk factors were selected on the basis of
previous known empiric association with mortality after pediatric cardiac
surgery12-14 supplemented by a small number of candidate variables
considered clinically important (sex, Down syndrome, prematurity).
The candidate risk factors considered in our analyses were sex, age band
(neonate, infant, child),12 calculated weight-for-age z-score,15 cardiac
diagnosis category, functionally univentricular heart (yes/no), specific pro-
cedure type category, operation type (bypass, nonbypass, or hybrid), bypass
time, acquired comorbidity, congenital comorbidity excluding Down syn-
drome, Down syndrome, additional cardiac risk factors, prematurity, and
severity of illness indicator.12 We previously published the method by
which the broad comorbidity groups that we used in this analysis were
derived from 776 individual conditions.16 In this study, we used exactly
the same comorbidity groups as in Brown and colleagues,16 and we sum-
marize these in Table 1. For the variables of cardiac diagnosis and cardiac
surgical procedure, we noted that there were many variables leading to
some categories being sparsely populated. Therefore, these 2 variable
groups were collapsed further to help with clinical interpretation. All sub-
categorizations were undertaken with reference to empiric data on risk of
early mortality.1,12-14 These categorizations are summarized in Table 1,
and details of how our previously published categories from Rogers and
colleagues12 were collapsed for this study of morbidity are provided in
Appendix E2.TABLE 1. Description of the approach to subcategorization of cardiac diag
Risk factor category Description
Cardiac diagnosis categories During the development of the
cardiac diagnosis categories w
and empirically derived risk
in a test dataset.
To develop models with risk fa
diagnoses into 5 groups, rank
severe, eg, hypoplastic left h
Specific cardiac procedure categories NCHDA developed an algorith
procedure categories for repo
To develop models with risk fac
(includes not a procedure gro
palliative or staging operation
(Appendix E2).
Comorbidity categories To develop models with risk fac
groups developed for pediatri
in the UK-based risk adjustm
These are (1) acquired comorbi
syndrome (eg, congenital def
factors (eg, cardiomyopathy,
preprocedure respiratory fail
(5) Down syndrome and (6) p
linked to postoperative morta
PRAiS, Partial Risk Adjustment in Surgery risk model (the UK-based method of risk stratific
Audit.
The Journal of Thoracic and CData Cleaning and Validation
To ensure accuracy of study data and complete case ascertainment for
incident morbidities, we took the following steps:
 Amonthly telephone conference call involving at least 1 person from all
sites discussed any ambiguous cases, and final case ascertainment was
agreed.
 A 3-month sample of data from each study site (January 1, 2016, to
March 31, 2016) was checked against an independent data source,
NCHDA, for 5 of the morbidities.
 A final reconciliation of morbidities was undertaken at the end of
the study when any cases with incomplete morbidity data were re-
viewed by the dedicated research nurse and a senior clinician at
the sites.Sample Size
In the original study protocol, we anticipated that between 3000 and
3300 surgical patients would be included across the 5 sites.11 On the basis
of morbidity rates from a previous study, we calculated that this was suffi-
cient to estimate accurately the incidence for morbidities occurring in at
least 2% of cases. In the event the incidence in isolation was less than
1.5% for 5 of the morbidities, this meant that for analysis of risk factors
for the primary morbidity outcome we needed to group morbidities for sta-
tistically robust analysis.
Primary Outcome
We used the following groupings of morbidity outcome for risk factor
analysis:
 Two categories—any morbidity versus none of the selected morbidities,
analyzed using multilevel logistic regression, accounting for multiple
procedures within patients.nosis, procedure, and comorbidity types for risk of morbidity modeling
of approach to subcategorization for risk modeling
PRAiS risk model12 for 30-d mortality after pediatric cardiac surgery, 28
ere ranked by an expert panel based on a combination of both complexity
of death, with the described independent validation of model performance
ctors for the outcome of morbidity, we further collapsed these 28 cardiac
ed by complexity and risk of death in the original study12 from A (most
eart syndrome) to E (least severe, eg, atrial septal defect) (Appendix E2).
m for grouping pediatric cardiac operations into relatively homogeneous
rting mortality outcomes.11
tors for the outcome of morbidity, we collapsed these 50 procedure groups
uping) into 3 broad categories of reparative or corrective operation,
, and ungrouped operation (where the approach could not be determined)
tors for the outcome of morbidity, we included the preexisting comorbidity
c cardiac procedures16 that appear as independent risk factors for mortality
ent model for 30-d mortality after pediatric cardiac surgery.12
dity (eg, renal failure, stroke), (2) congenital comorbidity excluding Down
ect of a major organ or genetic syndrome), (3) additional cardiac risk
pulmonary hypertension), and (4) severity of illness indicator (eg,
ure or shock). We also included for consideration of any link to morbidity
rematurity (gestational age<37 wk), although they were not statistically
lity.12
ation for early postoperative mortality); NCHDA, National Congenital Heart Diseases
ardiovascular Surgery c Volume-, Number- 3
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other than ECLS; multiple morbidity with no ECLS; and ECLS. This
grouping of outcomes enables the discrimination of risk factors for
the particularly adverse outcomes of ECLS and multiple morbidities
as identified a priori.17-21Analysis of Risk Factors for Primary Outcome
The prevalence of candidate risk factors is described with frequency
(%) for categoric factors and mean (standard deviation [SD]) or median
(interquartile range) as appropriate for continuous factors. For the outcome
of any selected morbidity versus no selected morbidity, the estimated ef-
fects are presented as odds ratios (ORs) and 95% confidence intervals
(CIs).
For the 4 category morbidity outcomes, we used multinomial logistic
regression with robust standard errors to adjust for clustering within pa-
tients. Estimated effects are presented as risk ratios (RRs) and 95% CI.
For both outcome groupings, we investigated whether the inclusion of
site as a random factor was important.
For both outcome groupings, univariate models were fitted for each
of the prespecified candidate risk factors, and the estimated effects of
the factors on morbidity outcome are presented along with 95% CIs.
All factors significant on univariate analysis (P<.1) were included in
the multivariable models. We state the number of missing values where
relevant in results. We used multiple imputation by chained equations to
account for missing data, and the imputation model included all risk
factors considered in the univariate analysis, which we assumed to
include all predictors of whether a data item would be missing. The
final multivariable models were derived by fitting a regression model
for all significant predictors, and estimates were combined using Ru-
bin’s rules.22 Model performance for the final multivariable models
was assessed using the c-statistic (area under the receiver operator
curve) and Hosmer–Lemeshow statistic. All analyses were performed
in Stata 14.23
Secondary Outcomes
The life status of patients in the study at 6 months after each operation
was determined using a combination of hospital records and NCHDA data
in March 2018. Thirty-day and 6-month mortality were attributed to the
first appearance of each patient in the dataset.TABLE 2. Number and percentage of procedure episodes affected by the
Of all 3090 procedures, the nu
(% [95% CI]) that had had the state
inclusive of combined morbidit
morbidities in isolation
Any morbidity 675 (21.8%)
Multiple morbidity 197 (6.4% [5.5-7.3])
ECLS 62 (2% [1.5-2.6])
Prolonged pleural effusion 202 (6.5% [5.7-7.5])
Feeding problems 184 (6.0% [5.1-6.8])
Unplanned reintervention 161 (5.2% [4.5-6.1])
Renal support 143 (4.6% [3.9-5.4])
Major adverse event 134 (4.3% [3.6-5.1])
Postsurgical infection 85 (2.8% [2.2-3.4])
Necrotizing enterocolitis 75 (2.4% [1.9-3.0])
Acute neurologic event 66 (2.1% [1.7-2.7])
CI, Confidence interval; ECLS, extracorporeal life support.
4 The Journal of Thoracic and Cardiovascular SurgerLength of stay was defined as the number of whole days between the
operation that led to the child entering the study and the date of discharge
from the specialist cardiac center. Two data sources (study database and
NCHDA) were cross-checked for accuracy.
Mortality within 6 months of each patient’s first procedure was
compared between patients with and without a morbidity using logistic
regression.
RESULTS
Descriptive Data
After removal of 10 misclassified procedures (minor and
excluded procedures, such as chest reopenings), 63 cardiac
operations that were undertaken within 30 days as part of
the planned treatment pathway, and all unplanned reopera-
tions within 30 days (a morbidity outcome, Table 2, there
were 161 in total), there were 3090 procedures meeting in-
clusion/exclusion criteria. These procedures pertained to
2861 patients, of whom 2648 had 1 surgical procedure,
197 had 2 surgical procedures, and 16 had 3 surgical
procedures.
Of the 3090 procedures included in the study, 1723
(56%) were reparative, 510 (16%) were palliative, and
857 (28%) were ungrouped. Of these procedure episodes,
414 (13.4%) were in functionally univentricular circula-
tions, 528 (17.1%) were in neonates, 1291 (41.8%) were
in infants, and 1271 (41.3%) were in children.
There was excellent concurrence between the study data
set and NCHDA; among the 443 patients in the 3-month
sample checked, 9 morbidities were present in the study da-
taset but not in NCHDA, and in no cases was a morbidity
recorded in NCHDA and not in the study dataset.
Incidence of Morbidities
We present the incidence of individual selected morbid-
ities as ‘‘any occurrence’’ (the total number of occurrencesvarious types of morbidity
mber
d morbidity,
ies and
Of all 3090 procedures, the number
(% [95% CI]) that had the stated morbidity
by itself as an isolated event
Not applicable
Not applicable
6 (0.2%)
111 (3.6% [3.0-4.3])
99 (3.2% [2.6-3.9])
59 (1.9% [1.5-2.5])
40 (1.3% [0.9-1.8])
34 (1.1% [0.8-1.5])
27 (0.9% [0.6-1.3])
32 (1.0% [0.7-1.5])
14 (0.5% [0.2-0.8])
y c- 2019
Brown et al Congenitalof a given morbidity both as part of a multi-morbidity and
as a standalone event) and ‘‘in isolation’’ (where the
morbidity occurred as a stand-alone event) in Figure 1
and Table 2. Given that we had an a priori interest in
ECLS as a severe adverse event, when ECLS occurred, pa-
tients were defined as ECLS morbidity irrespective of
other concurrent morbidities. The most common morbid-
ities as ‘‘any occurrence’’ were prolonged pleural effusion
(6.5%), feeding problems (6.0%), and unplanned reinter-
vention (5.2%). We prespecified in the protocol that mor-
bidities with a rate less than 1.5% could be considered
rare. All of the 9 selected morbidities had any occurrence
rate greater than 1.5%, the least common being an acute
neurologic event (2.1%). However, only 4 morbidities
occurred in isolation at a rate greater than 1.5%: prolonged
pleural effusion, feeding problems, unplanned reinterven-
tion, and ECLS.C
O
N
GMultiple Morbidities
Of 197 (6.4%) procedures that resulted in multiple
morbidity, 76 (39%) were with a feeding problem, 73
(37%) with an unplanned reintervention, 72 (37%) with
prolonged pleural effusion, 67 (34%) with major adverse
event, 66 (34%) with renal support, 49 (25%) with postsur-
gical infection, 34 (17%) with acute neurologic event, and0%
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FIGURE 1. Incidence of selected morbidities by procedure with 95% CIs. 1,
morbidities, as part of multi-morbidities and as part of ECLS. 2, In blue, the nu
The Journal of Thoracic and C33 (17%) with necrotizing enterocolitis. For the 197 multi-
ple morbidity cases, 140 involved 2 morbidities, 39
involved 3 morbidities, 17 involved 4 morbidities, and 1
involved 5 morbidities.ECLS Morbidities
Among the 62 (2%) procedures in which there was
postoperative ECLS, only 6 involved just ECLS and
no other morbidities, 37 (60%) ECLS morbidities
involved renal support; 33 (53%) were with major
adverse event, 29 (47%) were with unplanned reinter-
vention, 19 (31%) were with prolonged pleural effusion,
16 (29%) were with an acute neurologic event, 10
(16%) were with necrotizing enterocolitis, 9 (15%)
were with postsurgical infection, and 9 (15%) were
with a feeding problem.Risk Factors for Occurrence of Any Morbidity
Versus No Morbidity
Table 3 shows the frequency (%) for categoric risk fac-
tors and mean (SD) or median (interquartile range) as
appropriate for continuous risk factors. Weight was missing
or infeasible (>5 SD from the normative mean) in 186 pa-
tients, and for these we used multiple imputation to infer
their weight.n
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TABLE 3. Summary of risk factors by any morbidity outcome, with univariate and multivariable logistic regression results
No morbidity
(N ¼ 2415)
Any morbidity
(N ¼ 675)
Univariate OR
(95% CI) P value
Multivariable
OR (95% CI) P value
Male 1299 (53.8) 372 (55.1) 1.05 (0.89-1.25) .54 –
Median age (d), (IQR) 286 (105-1582) 102 (10-331)
Child (ref) 1111 (46.0) 160 (23.7)
Infant 1023 (42.4) 268 (39.7) 1.82 (1.47-2.25)<.001 1.61 (1.26-2.05)<.001
Neonate 281 (11.6) 247 (36.6) 6.10 (4.81-7.75)<.001 5.26 (3.90-7.09)<.001
Median weight (kg), (IQR) 7.7 (4.7-16.2) 4.6 (3.2-8.0)
Weight<mean for age 2 SD 714 (31.5) 234 (36.8) 1.27 (1.05-1.52) .01 1.21 (0.97-1.51) .09
Primary cardiac diagnosis
E (ref)–least severe/complex disease 1002 (41.5) 123 (18.2)
D 796 (33.0) 227 (33.6) 5.13 (3.79-6.93)<.001 2.02 (1.58-2.60)<.001
C 215 (8.9) 109 (16.2) 3.83 (2.85-5.13)<.001 1.44 (1.00-2.07) .05
B 232 (9.6) 109 (16.2) 4.13 (3.07-5.55)<.001 2.62 (1.85-3.71)<.001
A–most severe/complex disease 170 (7.0) 107 (15.8) 2.32 (1.83-2.94)<.001 2.14 (1.41-3.24)<.001
Univentricular heart 255 (10.6) 159 (23.6) 2.61 (2.11-3.23)<.001 1.55 (1.07-2.24) .02
Acquired comorbidity 337 (14.0) 119 (17.6) 1.32 (1.05-1.66) .02 1.33 (1.03-1.71) .03
Congenital comorbidity 537 (22.2) 178 (26.4) 1.25 (1.03-1.52) .03 1.28 (1.02-1.59) .03
Severity of illness risk 222 (9.2) 152 (22.5) 2.87 (2.30-3.58)<.001 1.52 (1.16-2.00)<.01
Premature birth 231 (9.6) 73 (10.8) 1.15 (0.87-1.51) .33 –
Downs syndrome 214 (8.9) 63 (9.3) 1.06 (0.79-1.43) .71 –
Additional cardiac risk factors 165 (6.8) 65 (9.6) 1.45 (1.09-1.94) .01 1.39 (0.99-1.94) .05
Procedure reparative/corrective (ref) 1391 (57.6) 332 (49.2)
Palliative/staged 331 (13.7) 179 (26.5) 2.27 (1.82-2.82)<.001 1.65 (1.14-2.38)<.01
Ungrouped or ambiguous 693 (28.7) 164 (24.3) 0.99 (0.81-1.22) .94 1.04 (0.82-1.31) .75
Median bypass time (min) (IQR) 72 (42-110) 110 (62-156)
No bypass (ref) 390 (16.2) 103 (15.3)
Up to 90 min 1148 (47.5) 150 (22.2) 0.48 (0.35-0.65)<.001 0.78 (0.57-1.09) .14
>90 min 877 (36.3) 422 (62.5) 1.76 (1.32-2.34)<.001 2.28 (1.67-3.12)<.001
Cardiac diagnosis group (main preoperative diagnosis) (A) hypoplastic left heart syndrome, truncus arteriosus, pulmonary atresia intact septum, (B) functionally univentricular
heart, pulmonary atresia ventricular septal defect, (C) transposition of the great arteries all types, interrupted aortic arch, totally anomalous pulmonary venous connection, (D)
patent ductus arteriosus, tricuspid valve anomalies, acquired heart disease, complete atrioventricular septal defect, (E) tetralogy of Fallot, mitral valve anomalies, isolated aortic
stenosis, aortic regurgitation, aortic arch obstruction, subaortic obstruction, ventricular septal defect, atrial septal defect. OR, Odds ratio; CI, confidence interval; IQR, interquar-
tile range; SD, standard deviation.
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syndrome, and low weight for age, all candidate risk factors
were statistically associated with any morbidity outcome in
multivariable analysis (Table 3 shows ORs and 95% CIs).
Inclusion of site made a negligible difference, and we pre-
sent results from the model without site. After adjustment
for other factors, agewas the most important risk factor: Ne-
onates had a 5.26-fold increased chance of morbidity, and
infants had a 1.61-fold increased risk compared with chil-
dren aged more than 1 year. Cardiac diagnosis group was
the next most influential factor, with the more complex con-
ditions carrying a higher risk of morbidity, followed by a
prolonged bypass time in excess of 90 minutes, which car-
ried a 2.8-fold increased risk. A palliative or staged6 The Journal of Thoracic and Cardiovascular Surgerprocedure and the presence of a functionally univentricular
heart both increased the chance of a morbidity 1.6 times
(these 2 factors clearly have some overlap). Severity of
illness factor (which includes preprocedure mechanical
ventilation or shock) increased the risk by 1.5 times.
The area under the receiver operator curve for the final
multiple logistic regression model for any morbidity was
0.77 (95% CI, 0.75-0.79), and Hosmer–Lemeshow good-
ness of fit was P ¼ .13, indicating reasonable calibration
of the model.
Risk Factors for the 4-Level Morbidity Outcome
The multinomial models for the 4-category outcome are
shown in Table 4. These analyses were in line with they c- 2019
TABLE 4. Multinomial regression results of risk factors for the 4-level morbidity outcome
Univariate RR
single vs none
(95% CI)
P value
Univariate RR
ECLS vs none
(95% CI)
P value
Univariate
RR multiple vs none
(95% CI)
P value
Multivariable RR
single vs none
(95% CI)
P value
Multivariable RR
ECLS vs none
(95% CI)
P value
Multivariable
RR multi vs none
(95% CI)
P value
Male 1.19 (0.97-1.48)
.10
0.62 (0.37-1.03)
.07
0.96 (0.72-1.29)
.79
– – –
Child (ref)
Infant 1.66
(1.29-2.13)
<.001
2.27
(1.10-4.68)
.03
2.20
(1.46-3.33)
<.001
1.49
(1.12-1.97)
<.01
2.00
(0.90-4.44)
.09
1.88
(1.21-2.92)
<.01
Neonate 4.44
(3.34-5.90)
<.001
10.06
(4.95-20.46)
<.001
10.28
(6.81-15.51)
<.001
3.79
(2.71-5.30)
<.001
7.47
(2.94-18.94)
<.001
10.52
(6.22-17.78)
<.001
Weight<mean for
age 2 SD
1.25 (1.00-1.57)
.05
1.09 (0.63-1.87)
.76
1.36 (0.99-1.85)
.05
1.23 (0.94-1.60)
.13
0.98 (0.51-1.88)
.95
1.26 (0.88-1.80)
.21
Cardiac diagnosis
E (ref–least severe)
D 1.88 (1.42-2.49)
<.001
4.20 (1.68-10.50)
<.01
3.57 (2.22-5.73)
<.001
1.63 (1.22-2.18)
<.01
3.12 (1.24-7.87)
.02
3.50 (2.14-5.72)
<.001
C 2.96 (2.07-4.23)
<.001
12.43 (4.81-32.13)
<.001
6.60 (3.84-11.36)
<.001
1.27 (0.85-1.92)
.25
2.20 (0.68-7.14)
.19
1.87 (0.96-3.62)
.06
B 2.93 (2.06-4.15)
<.001
8.64 (3.21-23.25)
<.001
6.12 (3.56-10.52)
<.001
1.88 (1.24-2.87)
<.01
8.53 (3.01-24.19)
<.001
4.54 (2.44-8.46)
<.001
A (most severe) 3.93 (2.74-5.63)
<.001
7.86 (2.69-22.93)
<.001
9.09 (5.30-15.57)
<.001
1.67 (1.03-2.71)
.04
4.29 (1.11-16.55)
.03
3.50 (1.71-7.16)
<.01
Univentricular heart 2.61 (2.02-3.37)
<.001
1.44 (0.70-2.94)
.32
3.04 (2.15-4.29)
<.001
1.54 (1.03-2.32)
.04
1.13 (0.35-3.63)
.84
1.80 (0.97-3.34)
.06
Acquired
comorbidity
1.27 (0.95-1.69)
.10
1.33 (0.69-2.57)
.40
1.43 (0.98-2.07)
.06
1.31 (0.97-1.77)
.08
1.15 (0.55-2.40)
.72
1.44 (0.95-2.20)
.09
Congenital
comorbidity
1.17 (0.91-1.49)
.22
1.43 (0.82-2.49)
.21
1.39 (1.01-1.91)
.05
1.19 (0.92-1.55)
.19
1.35 (0.71-2.54)
.36
1.46 (1.03-2.07)
.03
Severity of illness 2.17 (1.64-2.88)
<.001
6.67 (3.96-11.25)
<.001
3.54 (2.52-4.98)
<.001
1.28 (0.93-1.76)
.13
3.39 (1.74-6.61)
<.001
1.62 (1.07-2.44)
.02
Premature 0.92 (0.64-1.33)
.67
1.20 (0.54-2.67)
.65
1.63 (1.08-2.45)
.02
0.80 (0.54-1.19)
.28
1.11 (0.46-2.68)
.82
1.54 (0.97-2.43)
.07
Down syndrome 1.12 (0.79-1.60)
.52
0.90 (0.36-2.28)
.83
0.97 (0.58-1.62)
.91
– – –
Additional cardiac
risk
1.29 (0.90-1.86)
.17
2.02 (0.95-4.29)
.07
1.63 (1.02-2.60)
.04
1.26 (0.86-1.86)
.24
1.79 (0.75-4.30)
.19
1.61 (0.94-2.76)
.08
Procedure Reparative/
corrective (ref)
Palliative/staged 2.50 (1.93-3.22)
<.001
0.86 (0.40-1.86)
.71
2.36 (1.64-3.39)
<.001
1.87 (1.25-2.80)
<.01
0.71 (0.20-2.54)
.60
1.43 (0.77-2.67)
.26
Ungrouped 0.93 (0.72-1.21)
.61
0.77 (0.42-1.41)
.40
1.21 (0.86-1.72)
.28
0.95 (0.72-1.25)
.72
1.02 (0.52-1.99)
.96
1.32 (0.89-1.97)
.17
No bypass (reference)
Up to 90 min 0.48 (0.35-0.66)
<.001
0.25 (0.06-1.14)
.07
0.58 (0.35-0.97)
.04
0.69 (0.48-1.00)
.05
0.43 (0.10-1.90)
.26
1.15 (0.64-2.08)
.64
>90 min 1.39 (1.04-1.85)
.02
6.11 (2.20-16.99)
<.01
2.45 (1.56-3.84)
<.001
1.76 (1.24-2.50)
<.01
6.63 (2.43-18.07)
<.001
3.38 (1.95-5.84)
<.001
Cardiac diagnosis group (main preoperative diagnosis) (A) hypoplastic left heart syndrome, truncus arteriosus, pulmonary atresia intact septum, (B) functionally univentricular
heart, pulmonary atresia ventricular septal defect, (C) transposition of the great arteries all types, interrupted aortic arch, totally anomalous pulmonary venous connection, (D)
patent ductus arteriosus, tricuspid valve anomalies, acquired heart disease, complete atrioventricular septal defect, (E) tetralogy of Fallot, mitral valve anomalies, isolated aortic
stenosis, aortic regurgitation, aortic arch obstruction, subaortic obstruction, ventricular septal defect, atrial septal defect. RR, Risk ratio; CI, confidence interval; ECLS, extracor-
poreal life support.
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delineation of the risk for multiple morbidity and ECLS.
Neonatal status was even more strongly linked to ECLS
(RR, 7.9; 95% CI, 2.94-18.94) and multiple morbidity
(RR, 10.6; 95% CI, 6.22-17.78) than it was to morbidity
in general. Likewise, in the more complex cardiac diagno-
ses, especially groups A and B (encompassing hypoplastic
left heart syndrome, pulmonary atresia, truncus arteriosus,
and functionally univentricular heart), the RRs were 4.3
(95% CI, 1.1-16.6) and 8.2 (95% CI, 3.0-24.2) for ECLS
and 3.5 (95% CI, 1.1-7.2) and 4.5 (95% CI, 2.4-8.5) for
multiple morbidities, suggesting these were strongly linked
to these outcomes. The next most important risk factor for
both these outcomes was prolonged bypass time more
than 90 minutes. In particular, this was associated with a
6.6-fold risk of ECLS, noting that this intraoperative mea-
sure may reflect unexpected findings or technical challenges
at operation. Increased severity of illness (which includes
preprocedure mechanical ventilation or shock) was associ-
ated with a 3.7-fold higher incidence of ECLS and a 1.7-
fold risk for multiple morbidities. However, we advise
some caution in interpreting these results because theTABLE 5. Postoperative length of stay, 30-day survival, and 6-month surv
Morbidity type
Median length of postoperative
hospital stay in days (IQR)
No morbidity 8 d (5, 13)
Any morbidity 24 d (15, 42)
Single morbidities aggregated 20 d (13, 31)
Multi-morbidity 35 d (22, 56)
ECLS 43 d (20, 84)
Acute neurologic event 19 d (12, 39)
Unplanned reoperation 22 d (14, 33)
Feeding problems (feed) 20.5 d (12, 36)
Renal support (renal) 17 d (14, 26)
Major adverse event 16.5 d (8, 25)
Necrotizing enterocolitis 24.5 d (18.5, 49.5)
Surgical infection 20.5 d (11, 28)
Prolonged pleural effusion 20 d (14, 28)
IQR, Interquartile range; ECLS, extracorporeal life support.
8 The Journal of Thoracic and Cardiovascular Surgernumber of ECLS patients was relatively low and CIs are
wide. Surgical procedure category and univentricular heart
were not significant risk factors in this model.
Secondary Outcomes
There were 9 patients discharged alive for whom life sta-
tus information at 30 days was unavailable. Life status at
6 months was unavailable for 7 patients; these patients are
not included in the corresponding mortality results. Missing
date information for 9 patients led to them being excluded
from the length of stay analyses.
Of 2861 patients, 37 (1.3%) died within 30 days and 89
(3.1%) died within 6 months of their first procedure. Post-
operative length of stay, 30-day survival, and 6-month sur-
vival are shown in Table 5 by individual morbidity type.
Given that these were secondary outcomes, not subjected
to detailed risk modeling and included for descriptive pur-
poses, we do not present P values with this table. Postoper-
ative length of stay is depicted in Figure 2.
While acknowledging that we did not undertake detailed
risk models for our secondary outcomes of survival
6 months after operation and patient length of stay (bothival by individual morbidity type
30-d survival from first
procedure (N ¼ 2852)
6-mo survival from first
procedure (N ¼ 2845)
2216/2219
99.9% (99.6, 100)
2202/2217
99.3% (98.9, 99.6)
599/633
94.6% (92.6, 96.3)
554/628
88.2% (85.4, 90.6)
379/384
98.7% (97.0, 99.6)
365/381
95.8% (93.3, 97.6)
181/192
94.3% (90.0, 97.1)
158/190
83.2% (77.1, 88.2)
39/57
68.4% (54.8, 80.1)
31/57
54.4% (40.7, 67.6)
12/13
92.3% (64.0, 99.8)
12/13
92.3% (64.0, 99.8)
54/54
100% (93.4, 100)
50/54
92.6% (82.1, 97.9)
94/94
100% (96.2, 100)
90/91
98.9% (94.0, 100)
39/39
100% (91.0, 100)
37/39
94.9% (82.7, 99.4)
29/33
87.9% (71.8, 96.6)
28/33
84.9% (68.1, 94.9)
30/30
100% (88.4, 100)
28/30
93.3% (77.9, 99.2)
25/25
100% (86.3, 100)
25/25
100% (86.3, 100)
96/96
100% (96.2, 100)
95/96
99.0% (94.3, 100)
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FIGURE 2. Postoperative length of stay bymorbidity type. The boxplot shows the postoperative length of stay in days, for no selected morbidities (in blue),
for each of the selected morbidities in isolation, multiple morbidities, and ECLS (all in red). The middle heavy bar represents the median, the box represents
the IQR 25th (Q1) to 75th centiles (Q3), and the outer lines ending in a bar represent the range.
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were strongly associated with morbidity. The 6-month sur-
vival was significantly higher in those who had no selected
morbidity at 99.3% (95% CI, 98.9-99.6) than those who
had ‘‘any morbidity’’ at 88.2% (95% CI, 85.4-90.6;
P< .001). Patients with any single selected morbidity,
ECLS, or multi-morbidity had a significantly lower sur-
vival at 6 months compared with those with no selected
morbidity (P<.001). All morbidity groups had a signifi-
cantly longer length of stay than patients with no selected
morbidity.
DISCUSSION
This unique, large prospective multicenter study of the
incidence of important early morbidities after pediatric car-
diac surgery highlights some important points. Among 3090
procedures, 21.8% led to at least 1 of the selected morbid-
ities. Of these 3090 procedures, 6.4% led to multiple mor-
bidities and a further 2% led to ECLS, which in particular
may be considered a near-miss adverse event. The most
common of our included morbidities, all with rates greater
than 5%, were prolonged pleural effusion, feeding prob-
lems, and unplanned reoperation.
The patients who had none of the selected morbidities
had shorter lengths of stay than those with 1 or more of
the selected morbidities and were more likely to survive
to 6 months. Although patients with 1 or more selected
morbidity were more complex, the large differences weThe Journal of Thoracic and Creport in length of stay and survival at 6 months with
morbidity emphasize the importance of these events for pa-
tients and families, and as potential future metrics for
benchmarking.
The most important risk factors for the selected morbid-
ities, as has been shown in previous studies24-26 included
nonmodifiable risk factors of young age and more complex
cardiac diseases. In addition, children who deteriorated
before surgery requiring intensive care supports with
severity of illness factors, which may in some instances be
modifiable, were more likely to experience morbidity.
Prolonged cardiopulmonary bypass time, which again in
some cases be modifiable, was particularly associated with
the key outcomes of ECLS and multiple morbidities.
Our study complements the findings of a number of ini-
tiatives that illustrate growing attention worldwide on the
issue of surgical morbidity in this population, although a
notable difference in our study was the selection of a list
of morbidities incorporating perspectives from families
and clinicians working outside specialist centers.9 More-
over, our stated remit was to include morbidities that were
considered important based on prevalence and impact,
rather than an exhaustive list of every morbidity. We note
other important initiatives including activities of the Society
of Thoracic Surgeons Taskforce Subcommittee on Patient
Safety, which defined a range of unwanted events that
may contribute to postoperative morbidity, including com-
plications, adverse events, harm, medical error or injury,ardiovascular Surgery c Volume-, Number- 9
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Surgeons Registry data to develop a composite scores to
measure morbidity.25 A concern with this approach is that
specific morbidities that may be amenable to quality
improvement are less visible.
Prospective efforts include a Canadian study, which indi-
cated that prospective monitoring of complications may
lead to greater case ascertainment and thus a perception
of higher complication rates.24 The Pediatric Cardiac Crit-
ical Care Consortium (PC4) set up in 2009, with the aim
to improve the quality of care to patients with critical pedi-
atric and congenital cardiovascular disease in North Amer-
ica and abroad, provides partner sites who participate on a
voluntary basis with access to contemporary data for quality
improvement.28,29
A motivation for our study was that although routine
audit of postoperative mortality in pediatric cardiac sur-
gery is well established in the United Kingdom via the
NCHDA,11 stakeholders, including children’s heart sur-
gery programs, congenital heart patient support groups,
and the national audit, want to add morbidity outcomes
to the current reporting of mortality. In 2015 at the start
of our study, the NCHDA initiated the capture of prelimi-
nary morbidity measurements based on our study proto-
cols, but these outcomes have yet to be analyzed. The
collection of morbidities by the NCHDA will over time
enable a future registry-based study involving larger
numbers of patients, which might enable a method of
risk adjustment and national audit to be developed for
routine use.
Study Limitations
We included only risk factors for morbidity that were
available within mandatory and validated national audit
data. Although this means that centers can analyze their
ongoing case-mix with respect to these factors, we
acknowledge that there may be other risk factors that we
have not identified by taking this approach. It was necessary
to collapse the risk factors of cardiac diagnosis and cardiac
procedure into broad groups for our risk factor analyses,
thus limiting interpretation of our results when considering
specific individual conditions or procedures. Of note, we
took an approach of categorizing cardiac procedures into
3 broad groups and cardiac diagnosis into 5 groups. We
think cardiac diagnosis is an important factor to consider
in outcome analyses because we recognize that the most
complex patients may undergo a series of operations.
Although we undertook extensive quality checks on our
study data, no such processes are perfect. We found low
rates for certain morbidities as stand-alone events, and the
small numbers limited the risk factor analysis we were
able to undertake for these individual stand-alone morbid-
ities, for example, we did not have sufficient numbers to
analysis incidence by specific procedure.10 The Journal of Thoracic and Cardiovascular SurgeCONCLUSIONS
Our prospective multicenter study from the United
Kingdom complements the international efforts in this
important area. To assist with audit and quality assurance
initiatives, we have developed software for local moni-
toring of complication rates in the United Kingdom, and
we have co-developed information resources related to
these findings for parents who report on rates of the
selected morbidities, which will be available to UK-
based clinicians to use during the surgical consent process.
In the future, it is hoped that routine collection of impor-
tant morbidity measures will complement the collection
of mortality data by the national congenital heart diseases
audit in the United Kingdom.
Webcast
You can watch a Webcast of this AATS meeting presenta-
tion by going to: https://aats.blob.core.windows.net/
media/19%20AM/Tuesday_May7/202BD/202BD/S109%
20-%20Cardiopulmonary%20Bypass%20strategies/S109_
7_webcast_113446908.mp4.
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Dr Meena Nathan (Boston, Mass).
You have involved multiple people to
come up with your 9 important comor-
bidities, and it is important in future
studies that key stakeholders be
involved early in the process, and I
congratulate you on doing that in a
timely fashion.
I have several questions for you. In your morbidity anal-ardiovascular Surgysis, you analyzed on the basis of procedures rather than at
the patient level. How many of those 3090 procedures
occurred during the same hospitalizations? Were there
any that were counted twice during the same
hospitalization?
Dr David Barron (London, United
Kingdom). They would have to have
occurred during the hospital admission
to be counted as a morbidity.
Dr Nathan.My question was, you had
2861 patients but 3090 operations.
Dr Barron. Procedures, yes.
Dr Nathan. How do you account for
that?
Dr Barron. Of course, some of them were the same pa-
tients, such as a staged Norwood, they may have had their
stage I and II during the period of the study so they would
appear twice. If they had a reoperation during the same
admission and if it was within 30 days, it would not count
as a separate procedure. So you have to have 2 procedures
at least 30 days apart for them to be entered.
Dr Nathan. Were there some that occurred during the
same hospitalization?
Dr Barron. Yes.ery c Volume-, Number- 11
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went with which procedure?
Dr Barron. It goes back to the primary procedure in that
case.
Dr Nathan. You had a large sample size. I was
wondering whether you considered additional subgroup
analysis on the higher risk groups, such as neonates and
maybe on palliative versus nonpalliative procedures?
Dr Barron.Yes, that is all in process now, so there is a lot
of additional analysis that goes into particulars for each in-
dividual morbidity where we are studying the risk factors
for each individual morbidity and how it is affecting
survival.
Dr Nathan. And you did do a clustered analysis to ac-
count for center variation?
Dr Barron. Yes.
Dr Nathan. Did you consider analyzing volume of sur-
geon, volume of center as tertiles to look at variability?
Dr Barron. Exactly that, and we are doing it. There is
surprisingly little variation between the centers, but the
full analysis is still to come out. There are some real les-
sons. For instance, we don’t understand why but in Bir-
mingham we have a low incidence of need for renal
support. So we are intrigued to look into these sort of
things that the study has thrown up to see whether we
can learn from each other and if there is anything differ-
ently that others can learn from.
Dr Nathan. Have you decided of these 9 which are the 5
you are going to prospectively monitor and audit at all your
centers?
Dr Barron. It’s the ones that are easiest to define and
manage. So it’s going to be need for renal support and for
neurologic outcomes, a need for ECMO for unexpected re-
operations during admission and for major adverse events.12 The Journal of Thoracic and Cardiovascular SurgeDr Yves d’Udekem d’Acoz (Victoria,
Australia). David, I think it’s great
work. It is nice to have this large set
of data. I want to challenge you a bit
and see how do you practically react
to that? You have got your little app
and what do you do from there? Do
you go to your guys and say, hey,
guys, your rate of stroke is high, your babies are not feelingry c- 2019well, you have to do something. And then there are some
measurements that are not the same as the other ones, and
I was particularly happy to look at the rate of unplanned re-
operation, 5%, which is what I estimate it should be. I am
nervous when people tell me that they have a low rate of re-
operation, because you want to ultimately have the patient
get out of the hospital with a perfect operation even if it is
at the cost of a reoperation.
Dr Barron. Very well said, good, you are quite right, we
look at these things, but what are we going to do about it? I
think for some of them they might at least focus everybody
on the fact that things aren’t going as well as you might
think things are going. Things like infection rates, for
sure, I think you can react to them and do something about
it. For some of the others it may not necessarily be so easy,
but at least it heightens your awareness, and I think at least
you are armed a little bit with more information.
For reoperations, it’s difficult to standardize for it
because people’s thresholds for reoperation will be
different and you don’t quite know, as you say, when it be-
comes a good thing or a bad thing. So we will be going into
the whole analysis and looking at all the patients who had
reoperations to try and make sort of an understanding of
whether it reflected bad practice or whether it reflected
good practice.
APPENDIX
Appendix E1. Definitions of Morbidity, From Brown
and Colleagues10
Morbidity Timescale for identification Definition
Acute neurologic
event
Includes neurologic
morbidities that, based on
best clinical judgment,
arose as new findings
around the time of surgery
that were detected within
the same hospitalization as
the surgery. It is recognized
that in certain
circumstances such as
when a child is very sick on
life support, preprocedure
assessment is challenging,
in these circumstances as
full an evaluation as
possible to be completed,
incorporating serial
assessments over time.
Neurologic events, incl
seizure, abnormal
movement (includes
choreiform or atheto
focal neurologic defi
(includes hemiplegia
monoplegia), intracra
hemorrhage, stroke,
death, reversible isch
neurologic dysfuncti
hypoxic ischemic
encephalopathy, spin
ischemia, basal gang
damage, or brain stem
injury (includes abno
cough or gag reflex).
Unplanned
reoperation or
reintervention
Unplanned reinterventions are
procedures outside the
expected patient pathway,
which may be undertaken
at any time from the start of
the postoperative admission
up until 30 d after the
primary operation.
Additional procedures or
revisions undertaken within
the primary trip to the
operating theatre
(incorporating return onto
cardiopulmonary bypass)
are not included in the
definition of reoperation.
Unplanned reinterventi
include procedures th
were not intended du
the planning phase, f
an initial primary car
surgery, and result in
‘‘substantive alteratio
heart’’ incorporating
cardiac bypass, cardi
nonbypass, pacemak
placement, interventi
catheterizations, and
diaphragm plications
(which are not related
heart itself). The defi
does not include sup
other noncardiac surg
procedures.
Feeding
problems
A diagnosis of postoperative
feeding problems should be
considered during recovery
after surgery and before
discharge from the
specialist center to home or
to secondary care if the
child is unable to feed
normally. The goal is
detection of feeding
problems which are new
postsurgery, and it is
recognized that this may be
challenging where a child
A child may fail to feed
normally after pediat
cardiac surgery for a
of reasons including
gastroesophageal refl
vocal cord paralysis,
motor dysfunction, o
aversion, and neurolo
impairment.E2 If for
these reasons a child
able to orally feed or
completely orally fee
is tube dependent at
discharge from the te
The Journal of Thoracic and Card
Brown et al CongenitalMeasurement protocol (if
additional to definition)
Minimum treatment
protocol
uding
id),
cit
and
nial
brain
emic
on,
al cord
lia
rmal
E1
Includes new abnormality in
any of the following:
- Electroencephalogram
- Brain scan (computed
tomography or
magnetic resonance)
- Clinical evaluation
(seizures or movement
disorder, focal
neurologic signs,
generalized neurologic
signs, altered conscious
level including even
brain death)
The treatment protocol is
variable depending on the
type of neuro-morbidity.
Specialist consultation with a
neurologist, a full
evaluation of any brain
injury, and
neurodevelopmental
follow-up would be a
minimum.
ons
at
ring
ollow
diac
n to
ac
er
onal
to the
nition
port or
ery
Unplanned return to the
operating room or cardiac
catheter laboratory within
30 d (excludes
interventional catheters that
were planned
preoperatively; excluding
delayed chest closure,
excluding procedures for
bleeding)
(Includes diaphragm plication
and insertion of pacemaker
for surgically acquired
arrhythmia).
Not applicable. The minimal
assessment is
cardiovascular evaluation
of the repair with
echocardiography and
tolerance of weaning from
life supports.
ric
range
ux,
oral-
ral
gic
any of
is not
d and
rtiary
The requirement for any
feeding support.
Includes via the intravenous
route or via an enteral tube.
Excludes feeding support that
was present to treat a
primary problem diagnosed
before the surgery, feeding
support related to an
episode of necrotizing
enterocolitis, and feeding
support because the child
dislikes a special diet.
Treatment includes
assessment by the dietician,
speech and language
therapist, and of the
patient’s weight. Progress
with feeding should be
monitored by the clinical
care team responsible at
each stage of the journey.
(Continued)
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Morbidity Timescale for identification Definition
Measurement protocol (if
additional to definition)
Minimum treatment
protocol
was not fed preoperatively
for cardiac reasons because
feeding ability will not have
been assessed objectively.
center or at 30 d (if he or she
is otherwise clinically
stable enough to feed at that
time point), then a
postoperative feeding
problem will be diagnosed.
Need for renal
replacement
therapy
Includes renal replacement
therapy when initiated as a
new support at any time
from the start of the
postoperative admission to
ICU up to 30 d after the
primary operation.
The child requires renal
replacement therapy
(peritoneal dialysis or
hemofiltration) for renal
failure (oligo-anuria
of<0.5 mL/kg/h and
elevated creatinine level for
age) or fluid overload. In
patients in whom renal
support is required
alongside ECLS, the
primary morbidity is
viewed as ECLS.
The measurement protocol is
simply the presence of
(new) renal support.
(Excludes renal support on
ECLS.) Data on renal
biochemistry and urine
output will be collected.
Instigation of effective renal
replacement therapy.
If recovery of kidney function
does not occur within 3 to
5 wk then consultation with
pediatric renal physician is
required.
Major adverse
cardiac events
or never events
Events within this morbidity
may be identified during
the tertiary hospital stay
(ward or ICU) after the
primary surgery.
This morbidity includes:
- Cardiac arrest, where
the child receives any
chest compressions or
defibrillation.
- Chest reopening on the
ICU or ward for any
reason.
- Major hemorrhage in
the ICU after surgery.
- A ‘Never Event’
applicable to pediatric
cardiac surgery as
selected from the
‘Never Events’ list
published for National
Health Service for
2015E3 (Including
wrong site or wrong
patient surgery, wrong
prosthesis surgery,
retained foreign object
post procedure, wrong
route administration of
medication, transfusion
or transplantation of
main red cell group
incompatible blood
components or organs,
misplaced nasogastric
or orogastric tubes,
Major hemorrhage is defined
as bleeding>10 mL/kg/h
on ICU for 2 consecutive
hours.
A ‘Never Event’ includes the
events listed plus harm to
the patient, for example, if a
nasogastric tube is
misplaced, detected and
removed in a timelymanner
before any harm is done
then this is not a ‘Never
Event.’ Conversely, if the
misplaced nasogastric tube
is not noted, and feed is
given into the bronchus,
then this is a ‘Never Event.’
All events will result in
immediate treatment as part
of current practice.
(Continued)
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Continued
Morbidity Timescale for identification Definition
Measurement protocol (if
additional to definition)
Minimum treatment
protocol
- Tissue injury to limb or
vital organ such as
perforated viscus or
ischemic limb injury.
ECLS ECLS after surgery and before
discharge from the tertiary
hospital, including the rare
cases when a child was on
ECLS before surgery.
This morbidity is defined by
the presence of an ECLS
system connected to the
patient after the operation,
whether it was placed in the
operating theatre or in the
intensive care unit, and
whether the indication was
cardiac arrest, low cardiac
output state, poor cardiac
function, arrhythmia,
residual or recurrent
cardiac lesion, pulmonary
including pulmonary
hypertension or sepsis.
It is recognized that children
on ECLS after pediatric
cardiac surgery have high
rates of other
complications, including
renal support, bleeding,
sepsis, sternal reopening,
and cardiac arrest.E4 Where
such complications arise as
part of ECLS, the morbidity
is defined as ECLS.
The morbidity is in fact a
treatment modality offered
so this is not applicable.
Centers offering ECLS
follow protocols based on
those provided by the
ECLS organization.
Necrotizing
enterocolitis
Necrotizing enterocolitis as a
new diagnosis from after
surgery until discharge
from the tertiary hospital.
Necrotizing enterocolitis class
1a or 1b,E5 which
incorporates babies with
systemic signs of
inflammation and
abdominal clinical signs
such as distension or larger
than normal gastric
aspirates or mild rectal
bleeding but no radiologic
changes are included, if a
general surgery specialist
has seen the child and
commenced a course of
intravenous antibiotics and
parenteral nutrition for 5 to
7 d. Cases of severe
necrotizing enterocolitis
with radiologic signs
systemic instability and
bowel perforation are also
included.
Data in respect of systemic
clinical signs, intestinal
signs and radiology will be
collected, as well as the
treatments deployed, thus
enabling the necrotizing
enterocolitis diagnosis to be
graded between 1a and 3b.
Consultation with general
surgery and further
management in respect of
antibiotics, nutrition,
radiologic investigation,
and surgical intervention.
Surgical site
infection and
bloodstream
infection
Surgical site and bloodstream
infections diagnosed within
the hospital admission after
surgery or after
readmission to the same
unit during postoperative
recovery, where the treating
clinical team assesses the
infection to be linked to the
recent operation. It is noted
that mediastinitis may be
detected more than 30 d
Deep surgical site infection or
mediastinitis includes any
infection of an incised
wound that undergoes any
reintervention by a surgeon
(eg, opening of the wound,
vacuum dressing),
mediastinitis and false
aneurysm, independent of
culture positivity.
Bloodstream infection
includes both catheter
Deep surgical site infection
excludes superficial site
infection managed without
a surgeon’s reoperation by
conventional nurse dressing
only, even if the wound
heals by secondary
intention.
The minimum treatment
protocol consists of
antibiotics based on
organism and sensitivities,
and where relevant the
removal of the line.
Surgical intervention may
be required for deep
surgical site and in some
cases of endocarditis. Both
conditions require
(Continued)
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Morbidity Timescale for identification Definition
Measurement protocol (if
additional to definition)
Minimum treatment
protocol
after cardiac surgery,E6 thus
this time cutoff is not
applicable.
related and noncatheter
related. Cases have
systemic signs of infection,
a positive culture not
judged to be a contaminant,
and in the case of line
related a catheter in place
with positive cultures from
the line or from the line tip
when removed.
Endocarditis based on
clinical, imaging, or culture
evidence judged to be
diagnostic of endothelial/
endocardial infection and
its sequelae cardiac or
extra-cardiac.
prolonged antibiotic
therapy.
Prolonged pleural
effusion or
chylothorax
Prolonged pleural effusion is a
postprocedural effusion
with duration>10 d.
Chylothorax is diagnosed
from after surgery until
discharge from the tertiary
hospital.
Either a chylous pleural
effusion or significant
chylous pericardial
effusion or significant
chylous ascites or a
prolonged nonchylous
effusion that necessitates
thoracic drainage at least
10 d after index cardiac
surgery.
Chylous effusions are
characterized by milky
appearance and a pleural
fluid white blood cell count
of greater than 1000 cells/
mL with lymphocytes
greater than 80%.E7 If the
child is on normal feeds
the triglyceride level in the
pleural fluid will
be>1.1 mmol/L or the
ratio between the pleural
triglyceride level and the
serum triglyceride level
will exceed 1.
Diet consisting of medium
chain triglycerides or low
fat for chylothorax. On a
patient-by-patient basis
other treatments include
parenteral nutrition,
octreotide infusion,
intervention for venous
obstruction thoracic duct
ligation, and pleuradhesis.
ECLS, Extracorporeal life support; ICU, intensive care unit.
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Specific procedure groups
(A) Palliative or staged
(B) reparative or corrective
(C) ungrouped or
ambiguous
Group 1
Norwood procedure (stage 1) A
HLHS hybrid approach A
Group 2
TAPVC repair þ arterial shunt A
Truncus and interruption repair B
Truncus arteriosus repair B
Interrupted aortic arch repair B
Arterial switch þ aortic arch
obstruction repair (with or
without VSD closure)
B
Group 3
Arterial shunt A
Group 4
Repair of total anomalous
pulmonary venous connection
B
Arterial switch þ VSD closure B
Isolated pulmonary artery band A
Group 5
PDA ligation (surgical) C
Group 6
Arterial switch (for isolated
transposition)
B
Isolated coarctation/hypoplastic
aortic arch repair
B
Aortopulmonary window repair B
Group 7
Senning or Mustard procedure A
Ross-Konno procedure B
Mitral valve replacement C
Pulmonary vein stenosis procedure A
Pulmonary atresia VSD repair B
Tetralogy with absent pulmonary
valve repair
B
Unifocalization procedure (with/
without shunt)
A
Group 8
Heart transplant A
Tricuspid valve replacement C
Aortic valve repair B
Pulmonary valve replacement B
Aortic root replacement (not Ross) B
Cardiac conduit replacement C
(Continued)
Continued
Specific procedure groups
(A) Palliative or staged
(B) reparative or corrective
(C) ungrouped or
ambiguous
Isolated RV to PA conduit
construction
C
Tricuspid valve repair A
Group 9
Multiple VSD closure B
Atrioventricular septal defect and
tetralogy repair
B
Cor triatriatum repair B
Supravalvar aortic stenosis repair B
Rastelli - REV procedure B
Group 10
Bidirectional cavopulmonary shunt A
Group 11
Atrioventricular septal defect
(complete) repair
B
Group 12
Fontan procedure A
Group 13
Aortic valve replacement – Ross B
Subvalvar aortic stenosis repair B
Mitral valve repair B
Sinus venosus ASD or PAPVC
repair
B
Group 14
Atrioventricular septal defect
(partial) repair
B
Tetralogy and Fallot-type DORV
repair
B
Vascular ring procedure B
Group 15
Anomalous coronary artery repair B
Aortic valve replacement – non-
Ross
B
ASD repair B
VSD repair B
No specific procedure group
No specific procedure C
HLHS, Hypoplastic left heart syndrome; TAPVC, total anomalous pulmonary venous
connection; VSD, ventricular septal defect; PDA, patent ductus arteriosus closure; RV,
right ventricle; PA, pulmonary artery; ASD, atrial septal defect; PAPVC, partial anom-
alous pulmonary venous connection; DORV, double-outlet right ventricle.
Appendix E2. Cardiac Procedure Groups Based on
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Diagnosis groups Group
Group 1
HLHS A
Truncus arteriosus A
Pulmonary atresia and IVS A
Group 2
Functionally UVH B
Pulmonary atresia and VSD B
Group 3
TGAþVSD/DORV-TGA C
Interrupted aortic arch C
Group 4
PDA D
Group 5
Miscellaneous primary congenital diagnosis D
Tricuspid valve abnormality (including Ebstein’s) D
TAPVC C
Procedure N/A
Comorbidity N/A
Normal N/A
Empty/unknown N/A
Group 6
Acquired D
Group 7
AVSD D
Fallot/DORV Fallot E
Group 8
Aortic valve stenosis (isolated) E
Mitral valve abnormality E
Miscellaneous congenital terms E
Group 9
TGAþIVS C
Group 10
Aortic arch obstruction þ VSD/ASD E
Pulmonary stenosis E
Group 11
Subaortic stenosis (isolated) E
Aortic regurgitation E
VSD E
ASD E
Arrhythmia E
HLHS, Hypoplastic left heart syndrome; IVS, intact ventricular septum;UVH, univen-
tricular heart; VSD, ventricular septal defect; DORV, double-outlet right ventricle;
TGA, transposition of the great arteries; PDA, patent ductus arteriosus; TAPVC,
totally anomolous pulmonary venous connection; N/A, not available; AVSD, atrioven-
tricular septal defect; ASD, atrial septal defect.
Appendix E2. Cardiac Diagnosis Groups Based on
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Appendix E3. Case Mix and Volume by Center
Center by age bands
Brown et al CongenitalHospital site Neonate Infant Child Total
1. 120
12.26
444
45.35
415
42.39
979
100.00
2. 109
20.26
237
44.05
192
35.69
538
100.00
3. 130
17.91
259
35.67
337
46.42
726
100.00
4. 98
18.92
219
42.28
201
38.80
518
100.00
5. 71
21.58
132
40.12
126
38.30
329
100.00
Total 528
17.09
1291
41.78
1271
41.13
3090
100.00
Hospital site
Cardiac diagnosis complexity
TotalA B C D E
1 58
5.92
101
10.32
78
7.97
340
34.73
402
41.06
979
100.00
2. 47
8.74
42
7.81
59
10.97
175
32.53
215
39.96
538
100.00
3. 124
17.08
110
15.15
69
9.50
206
28.37
217
29.89
726
100.00
4. 32
6.18
67
12.93
62
11.97
184
35.52
173
33.40
518
100.00
5. 16
4.86
21
6.38
56
17.02
118
35.87
118
35.87
329
100.00
Total 277
8.96
341
11.04
324
10.49
1023
33.11
1125
36.41
3090
100.00
Hospital site
Procedure category
TotalA: Staged/palliative B: Reparative/corrective C: Ungrouped/ambiguous
1. 110
11.24
553
56.49
316
32.28
979
100.00
2. 72
13.38
323
60.04
143
26.58
538
100.00
3. 205
28.24
356
49.04
165
22.73
726
100.00
4. 86
16.60
266
51.35
166
32.05
518
100.00
5. 37
11.25
225
68.39
67
20.36
329
100.00
Total 510
16.50
1723
55.76
857
27.73
3090
100.00
Center by diagnosis category
Center by procedure
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